Latest news and press releases about Monopar Therapeutics Inc. (MNPR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase...
Price
| Price | $101.45 |
| Market Cap | $680M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.62 |
| EV / EBITDA | -37.08 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -13.08% |
| Return on Invested Capital | -16.89% |
| Return on Assets | -13.22% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AKBA · BCYC · CMPX · FDMT · FULC · GOSS · KALV
Explore sector: Healthcare · Biotechnology
More sections of MNPR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks